The experience on coronavirus disease 2019 and cancer from an oncology hub institution in Milan, Lombardy Region
- PMID: 32380430
- PMCID: PMC7188643
- DOI: 10.1016/j.ejca.2020.04.017
The experience on coronavirus disease 2019 and cancer from an oncology hub institution in Milan, Lombardy Region
Abstract
The outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related disease (coronavirus disease 2019 [COVID-19]) has spread rapidly to a pandemic proportion, increasing the demands on health systems for the containment and management of COVID-19. Cancer has been reported as a major risk factor for adverse outcomes of and death from COVID-19. We extracted data from the World Health Organization's progress reports and from the Italian Council of Medicine. In addition, we retrieved clinical data on patients with cancer and with confirmed COVID-19 in our institution. As of 2nd April 2020, 110,574 COVID-19 cases and 13,157 deaths have been reported in Italy, representing a global share of 5.1% and 28.9% for incidence and mortality, respectively. In Italy, we report the analysis of the Italian Medical Council on 909 patients who died from COVID-19; of whom, 16.5% were patients with cancer. The population was enriched with subjects with multiple comorbid non-communicable diseases, with less than 1% of the population presenting no comorbid conditions. At the patient level, we identified nine patients referred to our department in the last two months who were receiving standard-of-care or experimental medications in the curative and palliative settings. The median age was 68 years (range = 42-79 years), and patients carried a median of one comorbid condition (0-2); two of nine patients presented with severe COVID-19 and were receiving inpatient care. None of the patients receiving immunotherapy experienced severe adverse outcomes, and four patients were discharged with complete reversal of the clinical syndrome and SARS-CoV-2 clearance. Learning from the experience of countries with a high burden, efforts must be made to assure the access of patients with cancer to treatments, prioritising the cancer health interventions based on their intrinsic value and limiting the exposure to an unacceptable risk of infection for both health providers and patients. Any significant work in the design and implementation of health system actions, including clinical care, must be framed as an initiative under the global response agenda and through a community approach, with the intention of pursuing common goals to tackle COVID-19 and cancer, as 'One Community' working for 'One Health's.
Keywords: COVID-19; Cancer; Coronavirus; Hub; SARS-CoV-2.
Copyright © 2020 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Conflict of interest statement G.C. has received honoraria from Pfizer, Novartis, Lilly and Roche; fees for expert testimony and medical education from Pfizer and has participated in advisory boards for Pfizer, Roche, Lilly, Ellipses Pharma, Novartis, Seattle Genetics and Celltrion. A.M. and D.T. have no potential conflicts of interest to disclose.
Comment in
-
Risk of coronavirus disease 2019 in patients treated for cancer: An immune response-based hypothesis.Eur J Cancer. 2020 Jul;134:6-8. doi: 10.1016/j.ejca.2020.05.003. Epub 2020 May 18. Eur J Cancer. 2020. PMID: 32425367 Free PMC article. No abstract available.
-
Comment on "The experience on coronavirus disease 2019 and cancer from an oncology hub institution in Milan, Lombardy Region" and reflections from the Italian Association of Oncology Nurses.Eur J Cancer. 2020 Aug;135:8-10. doi: 10.1016/j.ejca.2020.05.022. Epub 2020 Jun 4. Eur J Cancer. 2020. PMID: 32521294 Free PMC article. No abstract available.
References
-
- World Health Organization Coronavirus disease 2019 (COVID-19) situation report - 73. https://www.who.int/docs/default-source/coronaviruse/situation-reports/2... Available at:
-
- National Statistics Institute (ISTAT) https://www.istat.it/it/archivio/235098 Available at:
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous